Vertex Pharmaceuticals Inc (NAS:VRTX)

$ 493.6405 3.6405 (0.74%) Market Cap: 127.13 Bil Enterprise Value: 121.23 Bil PE Ratio: 0 PB Ratio: 8.14 GF Score: 93/100

Q2 2024 Vertex Pharmaceuticals Inc Earnings Call Transcript

Aug 01, 2024 / 08:30PM GMT

Release Date Price: $505.78 (+2.03%)

Transcript 10-Q8-K

Key Points

Positve

Vertex Pharmaceuticals Inc (VRTX) reported strong Q2 2024 revenue growth of 6% year-over-year, reaching $2.65 billion.
The company increased its full-year product revenue guidance to a range of $10.65 billion to $10.85 billion, representing 9% growth compared to 2023.
Vertex Pharmaceuticals Inc (VRTX) is making significant progress in its pipeline, with multiple programs advancing rapidly, including the vanzacaftor triple combination for cystic fibrosis and suzetrigine for acute pain.
The company has secured regulatory endorsements for expanding its VX-880 trial in type 1 diabetes and is on track to initiate a Phase III trial for povetacicept in IgA nephropathy.
Vertex Pharmaceuticals Inc (VRTX) continues to expand its market reach, with strong commercial execution in cystic fibrosis and the early launch of CASGEVY for sickle cell disease and beta thalassemia.

Negative

Vertex Pharmaceuticals Inc (VRTX) reported a non-GAAP operating loss of $3.1 billion in Q2 2024 due to a $4.4 billion AIP R&D charge from the Alpine acquisition.
The company's non-GAAP tax rate for Q2 2024 was negatively impacted, resulting in a reported rate of negative 10% due to the non-deductible Alpine charge.
Vertex Pharmaceuticals Inc (VRTX) faces challenges in the launch of suzetrigine, with potential delays in formulary and payer adoption processes.
The company discontinued development of VX-634 and VX-668 for alpha-1 antitrypsin deficiency due to insufficient transformative efficacy.
Vertex Pharmaceuticals Inc (VRTX) is navigating regulatory and reimbursement challenges for CASGEVY, particularly concerning fertility preservation support for government-insured patients.

Operator

Good day, and welcome to the Vertex Pharmaceuticals' second-quarter 2024 earnings call. (Operator Instructions)

Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Pease go ahead.

Susie Lisa

Vertex Pharmaceuticals Inc - Senior Vice President, Investor Relations

Good evening, all. My name is Susie Lisa and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our second-quarter 2024 financial results conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President, Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer.

We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website. We will be making forward-looking statements on this call that are subject to the risks and uncertainties discussed in today's press release and in our filings with the Securities and Exchange Commission.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.